The Veil Platform restructures traditional PEG polymer repeats into a high-density architecture that removes immunogenic PEG epitopes and forms a dense hydration shield around the conjugated therapeutic. Pre-existing anti-PEG antibodies do not bind to Veil polymers and have low immunogenicity.
Veil’s polymer conjugates have improved PK, bioavailability, and stability. With tunable sizes and thermal responsiveness, Veil supports proteins, peptides, LNPs, and aptamers — all with minimal changes to the underlying therapeutic.
Thermal Phase Transition (LCST)
Veil polymers offer smart functionality through a tunable phase transition just below body temperature, enabling sustained release of conjugated or encapsulated drugs upon subcutaneous injection. This thermal responsiveness prolongs therapeutic exposure without complex formulation redesign. Combined with innate stealth and PK extension properties, it provides a powerful delivery modality for long-acting biologics.
High-Density Hydration Shield Around the Therapeutic
Aptamers
Veil polymers conjugated to aptamers significantly improve serum stability and circulation time while maintaining target affinity.
The high-density polymer shield prevents immune recognition, reducing clearance, and avoiding ADA formation. This stealth-enabled modality is ideal for direct conjugation to aptamers and in polymer-micelle delivery vehicles for antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs), where precision and immune invisibility are critical.
Lipid Nanoparticles (LNPs)
Veil LNPs enable repeat dosing with reduced clearance, allowing for greater buildup of therapeutic payloads.
Veil’s stealth lipids replace immunogenic PEG-lipids in LNPs with biocompatible polymers that reduce immunogenicity of existing formulations. Key attributes like stability and payload delivery are retained with minimal optimization.
Peptides & Proteins
Veil’s polymer platform enables both site-specific and multi-site conjugation to peptides and proteins, enhancing pharmacokinetics while minimizing immunogenicity.
Our stealth polymers extend half-life and improve stability, while preserving biological activity. The bottlebrush architecture allows rational design of conjugates that remain functionally active and undetectable to the immune system. This expands the therapeutic potential of biologics without compromising efficacy.